

**The notice contains important information that requires your immediate attention.  
Should you have any query about this notice, please seek independent professional advice.**

February 12, 2018

**To Policyowners of Manulife Investment Plus (“MI Plus”) / Manulife Investment Solutions (“MISo”) /  
Alpha / Alpha Regular Investor (“ARI”) / Matrix  
(each a “Plan” and collectively, the “Plans”)**

**Amendments of Disclosures in the Prospectus of the Underlying Fund  
with respect to the Use of Financial Derivative Instruments**

We would like to notify you of the following changes with regard to the following underlying fund (the “**Underlying Fund**”) corresponding to the following investment choices under the Plans, following our receipt of the notice of the Underlying Fund dated January 31, 2018 (the “**Shareholder Notice**”).

Name of Plan	Name of Investment Choice	Name of Underlying Fund	Share Class of Underlying Fund
MI Plus and MISo	Manulife Inv Fidelity China High Yield Fund (dist)	Fidelity Funds - China High Yield Fund	Class A-MINCOME (G)-USD (hedged)
Alpha, ARI and Matrix	MIL Fidelity China High Yield Fund		Class A-ACC-USD

We were informed of a decision taken by the board of directors of Fidelity Funds (the “**Directors**”) to amend certain disclosures in the prospectus of Fidelity Funds (the “**Prospectus**”) with respect to the use of financial derivative instruments. This decision has been taken to help investors more clearly understand the use of various investment instruments and techniques within the sub-funds of Fidelity Funds so that they, in turn, are better informed about the potential suitability of the sub-funds to their needs.

The Underlying Fund is a sub-fund of Fidelity Funds. Accordingly, the investment objective of the Underlying Fund using the definition “primarily” or “principally” will be amended to clarify the use of derivative instruments. Where the objective state that portfolios should be “primarily” or “principally” invested in specific asset classes, it will be made clear that this may be achieved through physical assets, derivatives or other such investment instruments. Please refer to the Shareholder Notice for further details on the amendments.

The following enhancements will be applicable to the Underlying Fund. The improvements will be implemented by amending the general investment policy of the Underlying Fund as follows:

- 1) Introducing an enhanced description of the types of derivative instruments used and the purpose for which they are used.
- 2) Where the use of derivatives is currently permitted for the “generation of additional capital or income”, it will be clarified that this also includes the use of derivatives “for investment purposes on a non-extensive basis”. This means that derivatives may be used to gain or increase exposure to an underlying asset (as distinct from hedging or risk reduction) but in such a way that it does not increase the level of risk that a fund can take in line with its investment objective.

Please refer to the Shareholder Notice for the full text of the above enhancements.

These changes will come into effect on February 28, 2018 or such later date as may be decided by the Directors.

Upon the changes taking effect, exposure to the primary investments of the Underlying Fund may be obtained through means that are both direct and indirect e.g. using derivatives to obtain exposure to the underlying assets. None of the amendments described above will change the existing risk profile of the Underlying Fund as described in the Prospectus or change the manner in which the Underlying Fund is currently being managed.

It is expected that the Underlying Fund will not use derivatives extensively for investment purposes as a result of the proposed changes as the current extent / usage of derivatives by the Underlying Fund are expected to remain unchanged.

Furthermore, there will be no change to the current fee structure of the Underlying Fund as a result of the changes described.

The rights or interests of existing investors of the Underlying Fund will not be materially prejudiced as a result of the proposed changes outlined above.

Any costs in connection with the proposed changes will be borne by the management company of the Underlying Fund.

Please refer to the Shareholder Notice and the offering documents of the Underlying Fund for further information relating to the above changes.

If you have any enquiry, please do not hesitate to contact your Manulife Insurance Advisor or call our Customer Service Hotline at (852) 2108 1110 (in relation to MI Plus and MISo), (852) 2510 3941 (in relation to ARI, Alpha and Matrix) and (853) 8398 0383 in Macau during office hours: 9:00am - 6:00pm, Monday to Friday.

Customer Services

Individual Financial Products

**Manulife (International) Limited**

*Incorporated in Bermuda with limited liability*